A new analysis presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is adding to a growing body of evidence that GLP-1 receptor agonists — the medication class behind blockbuster drugs like Ozempic, Wegovy, and Mounjaro — may carry health benefits well beyond weight loss and blood sugar control. Among women with overweight or obesity, GLP-1 use was associated with roughly a 30% lower risk of developing breast cancer.
The findings, published in JCO Oncology Practice, are observational and preliminary. They do not prove that GLP-1 drugs prevent cancer. But the size of the effect, the plausibility of the mechanisms, and the scale of the dataset have caught the attention of oncologists and endocrinologists alike.
What the Study Found
Researchers at the University of Pennsylvania analyzed health records for 111,646 women between the ages of 45 and 80, all with a body mass index of 25 or higher, drawn from the Penn Medicine system. Within that group, 15,264 women (13.7%) had been prescribed a GLP-1 receptor agonist, while 96,382 had not.
After adjusting for confounders, GLP-1 users showed:
- 35.1% lower odds of being diagnosed with breast cancer in the full cohort
- 30.5% lower odds in a more rigorously matched subgroup that aligned users and non-users on age, BMI, comorbidities, and other risk factors
“The key takeaway is that we found an association between GLP-1 use and breast cancer incidence,” lead investigator Dr. Elizabeth McDonald told media at the ASCO meeting. She and her colleagues emphasize that the relationship is statistical, not causal — a distinction that matters when interpreting headlines.
Why Weight, Inflammation, and Insulin Matter for Breast Cancer Risk
The link between excess body fat and several cancer types, including postmenopausal breast cancer, is well documented. According to the World Health Organization’s International Agency for Research on Cancer (IARC), there is sufficient evidence that excess body fatness raises the risk of at least 13 cancer types, with postmenopausal breast cancer among them.
GLP-1 receptor agonists work by mimicking a gut hormone that boosts insulin release, slows gastric emptying, and reduces appetite. The result is meaningful, sustained weight loss for many people who take them — often 10% to 20% of body weight in clinical trials of semaglutide and tirzepatide.
Several mechanisms could plausibly link that weight loss, and the metabolic changes that come with it, to lower breast cancer risk:
Lower Estrogen Exposure
After menopause, adipose (fat) tissue becomes a primary source of estrogen production. More fat tissue tends to mean higher circulating estrogen levels, which can fuel the growth of hormone receptor-positive breast cancers — the most common subtype. Significant weight loss reduces this estrogen pool.
Reduced Chronic Inflammation
Excess adipose tissue, especially around the abdomen, secretes inflammatory signaling molecules such as TNF-α, IL-6, and leptin. Chronic low-grade inflammation is increasingly understood to play a role in cancer initiation and progression. GLP-1 drugs appear to dampen several of these inflammatory pathways.
Better Insulin Sensitivity
Insulin resistance and high circulating insulin levels — common in obesity and type 2 diabetes — have been associated with greater risk of several cancers. Research published in the Journal of the National Cancer Institute has linked elevated insulin and insulin-like growth factor (IGF-1) signaling to breast cancer progression. GLP-1 receptor agonists improve insulin sensitivity, potentially reducing these growth signals.
Important Caveats Before You Read the Headlines
The study has real limitations that researchers themselves flag. It is observational, meaning it can identify associations but cannot establish that GLP-1 drugs are causing the lower cancer rates. Several other factors could be at play:
- Women prescribed GLP-1 drugs may differ in ways the analysis could not fully capture — from healthcare engagement and screening frequency to lifestyle factors and access to care.
- The analysis did not distinguish between specific GLP-1 medications, duration of use, or dose — all of which could influence the apparent effect size.
- Genetic risk factors, family history, alcohol intake, and hormone therapy use were not fully accounted for.
- Cancer subtype and stage were not reported, leaving open the question of whether GLP-1 use is linked to fewer tumors overall, fewer aggressive tumors, or simply earlier detection.
The authors describe the results as “promising but preliminary.” A planned randomized trial, called INSPIRE, is being designed to investigate the biological mechanisms in a controlled setting.
How This Fits the Broader Evidence on GLP-1 Drugs
The Penn analysis is the latest in a series of studies hinting that GLP-1 receptor agonists may carry health benefits beyond glycemic control and weight loss. The SELECT trial, published in The New England Journal of Medicine in 2023, found that semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and pre-existing cardiovascular disease — even without diabetes.
Subsequent analyses have suggested potential benefits across kidney disease, sleep apnea, fatty liver disease, and certain neurodegenerative conditions. Cancer is a newer frontier. A 2024 study in JAMA Network Open reported associations between GLP-1 use and lower rates of 10 obesity-related cancers in people with type 2 diabetes, though that work had similar observational limitations.
Researchers caution that the cancer signal could partly reflect benefits already attributable to substantial weight loss, regardless of how that weight loss is achieved. Bariatric surgery, for example, has been linked in long-term studies to reduced cancer risk — particularly among women.
What This Means for People Considering or Taking GLP-1 Drugs
For people already taking a GLP-1 medication for diabetes, obesity, or cardiovascular risk reduction, the findings are reassuring rather than action-changing. They add another potential long-term upside to a medication class whose benefits and trade-offs are still being mapped.
The data should not be read as a reason to start a GLP-1 drug specifically to reduce cancer risk. These medications carry meaningful side effects — including nausea, gastrointestinal symptoms, and potential muscle mass loss with rapid weight reduction — and randomized trial evidence on cancer prevention does not yet exist.
Established, evidence-backed steps women can take to reduce breast cancer risk remain the foundation of prevention:
- Maintaining a healthy body weight, particularly after menopause
- Following recommended mammography screening schedules based on age and risk profile
- Engaging in regular physical activity — the American Cancer Society recommends 150–300 minutes of moderate or 75–150 minutes of vigorous activity weekly
- Limiting alcohol intake, which research has consistently linked to higher breast cancer risk
- Discussing family history and genetic testing with a healthcare provider when relevant
The Bigger Picture
The new analysis is best understood as a signal worth investigating, not a verdict. It joins a body of evidence suggesting that the metabolic changes driven by GLP-1 drugs — less inflammation, less circulating insulin, smaller adipose mass — may ripple through the body in ways researchers are still cataloguing.
Whether the apparent breast cancer benefit holds up in randomized trials remains an open question. For now, the prudent reading is that GLP-1 medications appear to do many useful things for metabolic health, and the cancer data is one more reason to study them carefully — not a reason to rewrite prevention guidelines.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.